$ROIV News

FDA Clears First Targeted Dermatomyositis Treatment From Roivant

Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis - Slideshow

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately

Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46

Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?

Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?

Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon

Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42

HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41

Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

Roivant Sciences Ltd. 2026 Q1 - Results - Earnings Call Presentation

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)